![](/images/2013/post-sep.jpg)
Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024
/EIN News/ -- SOUTH SAN FRANCISCO, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host a Research Forum to highlight its pipeline of next-generation ADCs. The live webcast will be held on Thursday, October 10, 2024, starting at 1:30 p.m. PT / 4:30 p.m. ET.
Webcast Information:
To access the live audio webcast on Thursday, October 10, at 1:30 p.m. PT / 4:30 p.m. ET, please go to https://ir.sutrobio.com/news-events/ir-calendar
An archived replay of the webcast will be available on the Company’s website following the live presentation.
About Sutro Biopharma
Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, to transform what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates Sutro’s continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.
![](https://ml.globenewswire.com/media/NTEwMTc3MTQtY2RjMS00YzhhLWE5ZmYtNDg3YzRkYzJiMDczLTExMzUzMzU=/tiny/Sutro-Biopharma-Inc-.png)
Contact Emily White Sutro Biopharma (650) 823-7681 ewhite@sutrobio.com
![](https://researchreports.einnews.com/tracking/article.gif?aid=742565233§ion=globenewswire&a=TXdVMkURTxu5XcqT&i=1w4mkrIppXfNGJXu)
Distribution channels: Culture, Society & Lifestyle, Technology ...
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Submit your press release